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ABSTRACT 
MicroRNA Regulation of IGF. (May 2013) 
 
Kayla Anne Filan McEnery 
Department of Biochemistry & Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Fardia Sohrabji  
Department of Neuroscience and Experimental Therapeudics 
Stroke is the fourth leading cause of death worldwide. Low levels of IGF-1, a known 
neuroprotectant, correspond to aging and increased severity of stroke. We have previously 
demonstrated that there is an inverse relationship between the presence of anti-let7f or anti-
miR-1 and levels of IGF-1. Further, the localization of let-7f was found to be within the 
microglial cell population. We hypothesize that let7f and miR-1 directly bind to the 3’ UTR 
region of IGF-1. Microglial cells (EOC-20) will be transfected with an IGF-1 clone with a 
luciferase tag. IGF-1 synthesis following treatment with antagomirs to either miR-1 or let7f 
will be tested by a luciferase assay.  
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CHAPTER I 
INTRODUCTION 
 
On average, stroke is the leading cause of death worldwide (Beal 2010). In the United States 
each year on average 800,000 people have a stroke. There are many risk factors for stroke 
including environment, age and gender. Interestingly enough, post-menopausal women have 
a higher risk of stroke than men. It has also been shown that women are more functionally 
affected after a stroke than men (Wyller 1997). This striking statistic makes the need for a 
stroke therapy more prevalent. Currently, there is only one FDA approved treatment known 
as tissue Plasmogen Activator (Lisabeth 2006). Overall, women receive this treatment 30% 
less often than men (Reeves 2009).  It has been speculated, that due to the disparity between 
symptoms and overall treatment, women are usually more severely disabled than men.    
 
IGF-1 is a known neuroprotectant. There is known direct correlation between low levels of 
IGF-1 and increased severity of stroke, especially in women.  This is seen throughout the 
female rat stroke model. A low level of IGF-1 is also associated with aging, a key factor in 
stroke severity. Thus identifying regulatory elements that increase IGF-1 levels will be 
crucial in potential treatment options for stroke. MiRNAs, a class of non-coding RNA, are 
key negative regulators of many pathways that can be exploited for stroke therapy.  
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MiRNAs are small noncoding RNAs which have been found to regulate many key pathways. 
MiRNAs have been found to be potential therapeutic targets in cancer, skeletal and muscle 
degenerative diseases and cardiovascular diseases (Sibley 2011, Dangwall 2012). There are 
several miRNAs that have been associated with stroke including, let-7f, miR-1, miR-126, 
miR-1259, miR-142-3p, -15b etc. (Tan 2009).  
 
According to bioinformatics, there is a potential binding site of let-7f and/or miR-1 on the 3’ 
UTR region of IGF-1. We have previously shown that anti-let7f and anti-miR1 treatment was 
able to mimic and even extend the neuroprotection due to IGF-1. Furthermore, anti-let7f 
treatment also increases the levels of microglial IGF-1. We hypothesize that miR-1 and Let7f 
directly binds to the 3’ UTR region of IGF-1 to regulate expression of this growth factor. In 
order to confirm this relationship in vitro, we will transfect an IGF-1 construct into a 
microglial cell line. Antagomir to either miR-1 or let7f will be added to these cells and IGF-1 
regulation will be determined by a luciferase reporter assay.   
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CHAPTER II 
METHODS 
Cell Culture 
(LADMAC) were purchased from American Type Culture Collection (ATCC). Cells were 
grown in EMEM with 10% Fetal Bovine Serium (FBS) at 37
o
C. After two weeks, the 
conditioned media was filtered and stored at -20
o
C to be added to the EOC media. EOC-20 
were purchased from ATCC. Cells were grown in EMEM with 10% FBS and 20% 
conditioned media from LADMAC at 37
o
C. Media was changed weekly and cells were split 
when confluence levels were approximately 80%. 
 
Optimizing Transfection Procedure:  
EOCs were harvested and counted prior to transfection. After counting the cells, the cells 
were centrifuged at 100g for 5 minutes. The pellet was resuspended in the transfection buffer 
and concentrations of 50 pmol, 100 pmol or 150 pmol of Flourescent Labeled Negative 
Control A Oligos (Exiqon) was added to 100,000 cells. Electroporation buffer was added to 
the NEON instrument. The EOCs were transfected using a NEON electroporator for 30 ms at 
1900 V for one pulse. The optimal concentration of oligos was found to be 100 pmol. Next 
the conditions for transfection were optimized by varying the voltage and the number of 
pulses.  
 
Transfections: (not optimal protocol)  
EOCs were harvest and counted prior to transfection. After counting the cells, the cells were 
centrifuged at 100g for 5 minutes. The pellet was resuspended in the transfection buffer and 
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1ug of the miRNA 3’UTR target clone (Genecoppia) per 100,000 cells. Eletroporation buffer 
was added to the cell. The cells were then transfected using a NEON electroporator for 20ms 
at 1200V for two pulses. Cells were transferred from the electroporation tubes to fresh 
warmed media into a 6 well plate.  
 
Luciferase Assay:  
Binding affinity for miRNA to the 3-UTR of IGF was measured using the Dual-Glo 
Luciferase Assay System purchased from Promega. The protocol was run according to 
manufacturer’s instructions. 
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CHAPTER III 
RESULTS 
Transfections of microglial cell line have resulted in a 20% transfection efficiency. The 
desired efficiency is at least 90% of positively transfected cells. This process must be 
optimized effectively before being able to proceed.  
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CHAPTER IV 
DISCUSSION 
Bioinformatic analysis was done using Targetscan. Due to the percentage of 
complementation it is likely that miR-1 and let-7f will directly bind to the IGF-1 3’ UTR. In 
order to confirm this hypothesis, transfections of EOC-20 cells were attempted. A variety of 
parameters were manipulated in order to determine an optimal transfection protocol. These 
included the cell number, conditions of growth, concentration of oligos, voltage, number of 
pulses and path length. The efficiency of transfection has not reached the required 90% of 
positively transfected cells to proceed to the next step of the project.  
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CHAPTER V 
CONCLUSION 
Based on previous published data, we have concluded that there is an interaction between 
IGF-1 and several miRNA, including miR-1 and let-7f. To determine if the interaction 
demonstrated is a direct interaction, a series of transfections were set up. Unfortunately, the 
transfection efficiency has not reached the optimal 90% positively transfected cells in order 
to accurately confirm a direct interaction.  
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